info@etrs2025.eu

ETRS ANNUAL MEETING 3 - 5 September 2025

Young Investigator Pre-conference
on 2nd of September 2025

Sessions

This page was updated on May 19th 2025.

ETRS 2025 Sessions

Each session consists of one session keynote by an invited speaker, guest speakers and a number of oral presentations selected from abstracts.

Charles Lapière Memorial Lecture

WED 03/09 | 16.30 – 17.30

Honorary Lecture by Dame Professor Molly Stephens

Oxford University, UK

New bioengineering-based approaches for therapeutics and biosensing in tissue repair

SESSION 1 | 3D-Printing, Biomaterials & Bioengineering

WED 03/09  |  10.00 – 12.00

Session Keynote by Professor Liam Grover

University of Birmingham, UK

Title to be confirmed

Guest Speaker

Dr. Oommen Oommen

SMART HYALURONAN HYDROGELS FOR INDUCING PRO-HEALING MACROPHAGE RESPONSES AND NEURONAL REGENERATION.

Abstracts

SESSION 2 | Stem Cells & Regenerative Medicine

WED 03/09  |  13.15 – 15.30

Session Keynote by Professor Paul Genever

University of York, UK

Title to be confirmed

Guest Speaker

Dr. Laura Howard

ENGINEERING EYE-LIKE ORGANOIDS AND TISSUES FROM HUMAN IPS CELLS: APPLICATIONS FOR REGENERATIVE MEDICINE.

Abstracts

SESSION 3 | Infection, Inflammation & Wound Healing

THU 04/09  |  08.30 – 10.05

Session Talk by Professor Matthew Hardman

University of Hull, UK

Title to be confirmed

Abstracts

SESSION 4 | Scarring & Wound Regeneration

THU 04/09  |  10.30 – 12.15

Session Keynote by Dr. Claire Higgins

Imperial College London, UK

Title to be confirmed

Guest Speaker

Dr. Soma Meran

CAN WE MODIFY HYALURONAN MATRIX TO PROMOTE RENAL RECOVERY AFTER INJURY?

Abstracts

SESSION 5 | Drug Development for Wound Healing – QBiotics Symposium

THU 04/09  |  13.15 – 15.05

Session Talk by Dr. Paul Reddell

QBiotics Group, Australia

Session Talk by Prof. David Thomas

Cardiff University, UK

Session Talk by Dr. Jason Cullen

QBiotics Group, Australia

Session Talk by Dr. Emma Woods

QBiotics Group, Australia

Session Talk by Prof. Ryan Moseley

Cardiff University, UK

Abstracts

SESSION 6 | ETRS Young Investigator Award

THU 05/09  |  15.30 – 17.30

Selected talks by ETRS Young Investigator Awardees

Invited Lecture by WHS Young Investigator Award Winner 2025, Veronika Jurczuk, University of Miami, USA  –  Statin-Cyclodextrin Hydrogels Accelerate Healing In Multiple Pre-Clinical Wound Models.

Selected Talk by Dr. Suwelack Corporate Foundation YIA Award Winner

 

Titles to be confirmed

SESSION 7 | Wound Healing Therapy Translation, Regulation & Public Perception (Workshop)

FRI 05/09  |  08.30 – 10.35

Session Talks by Dr Paul Reddell, Dr Paul Genever, Dr Matthew Malone, Dr Lindsey Davies, Dr Maki Umemura

QBiotics Group, Australia; University of York, UK; Convatec Wound Care, UK; NextCell Pharma, Sweden; Cardiff University, UK

Paul Reddell: Background & Introduction to the workshop.

Maki Umemura: Shifting Perceptions: Comparative perspectives on Regenerative Medicine Development.

Matthew Malone: What does medtech look for in terms of the development and commercialisation of new wound healing therapies?

Lindsay Davies: Regulatory considerations surrounding regenerative medicine therapy translation and commercialisation.

Paul Genever: University Spin-Out of Therapeutic Research – From Academia to SME.

Abstracts

SESSION 8 | Matrix Modulation of Tissue Repair

FRI 05/09  |  11.00 – 12.55

Session Keynote by Professor Tero Järvinen

Tampere University, FINLAND

Systemically administered, target-specific therapies for tissue repair.

Guest Speaker

Prof. Denis Barritault, OTR3, France

ARE HEPARAN SULFATES THE LEAD TO REACH THE GRAIL OF TISSUE REGENERATION?

Guest Speaker

Prof. Susan Volk, University of Pennsylvania, USA

TBC

Abstracts

SESSION 9 | Exploiting Biologics for Enhanced Healing

FRI 05/09  |  13.30 – 15.15

Session Keynote by Dr Ning Xu Landen

Karolinska Institute, SWEDEN

Decoding the RNA regulome of human skin wound healing – Towards future wound care.

Guest Speaker

Prof. Tim Bowen, Cardiff University, UK

MICRORNAs AS DISEASE SENTINELS AND THERAPEUTIC TARGETS IN PATIENTS WITH KIDNEY DISEASE.

Abstracts